Cancers, Vol. 11, Pages 1844: Mutations in Splicing Factor Genes in Myeloid Malignancies: Significance and Impact on Clinical Features Cancers doi: 10.3390/cancers11121844 Authors: Valeria Visconte Megan O. Nakashima Heesun J. Rogers Components of the pre-messenger RNA splicing machinery are frequently mutated in myeloid malignancies. Mutations in LUC7L2, PRPF8, SF3B1, SRSF2, U2AF1, and ZRSR2 genes occur at various frequencies ranging between 40% and 85% in different subtypes of...
02:00
Cancers, Vol. 11, Pages 1843: Tumour-Secreted Protein S (ProS1) Activates a Tyro3-Erk Signalling Axis and Protects Cancer Cells from Apoptosis Cancers doi: 10.3390/cancers11121843 Authors: Nour Al Kafri Sassan Hafizi The TAM subfamily (Tyro3, Axl, MerTK) of receptor tyrosine kinases are implicated in several cancers, where they have been shown to support primary tumorigenesis as well as secondary resistance to cancer therapies. Relatively little is known about the oncogenic role of...
02:00
Cancers, Vol. 11, Pages 1842: A Review of the Potential Role of Human Cytomegalovirus (HCMV) Infections in Breast Cancer Carcinogenesis and Abnormal Immunity Cancers doi: 10.3390/cancers11121842 Authors: Jürgen Geisler Joel Touma Afsar Rahbar Cecilia Söderberg-Nauclér Katja Vetvik Previously recognized classical human onco-viruses can regulate complex neoplastic events, and are estimated to play a role during carcinogenesis in 15–20% of cancer cases. Although the...
02:00
Cancers, Vol. 11, Pages 1845: Myoinvasive Pattern as a Prognostic Marker in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma Cancers doi: 10.3390/cancers11121845 Authors: Ignacio Ruz-Caracuel Jorge L Ramón-Patino Álvaro López-Janeiro Laura Yébenes Alberto Berjón Alicia Hernández Alejandro Gallego Victoria Heredia-Soto Marta Mendiola Andrés Redondo Alberto Peláez-García David Hardisson Low-grade and early Federation for Gynecology and Obstetrics...
02:00
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
07:06
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
07:06
Future Oncology, Ahead of Print.
06:08
The high-throughput sequencing has become a standard tool for analyzing gene expression. Usually a cDNA/DNA library is constructed with 5' and 3' linkers and then sequenced. Unlike mRNA, small RNA often contains modifications including 5' cap or triphosphate and 3' methylation, affecting the linker addition during cloning processes. Small RNA is expressed at much lower levels than mRNA, making it more difficult to clone small RNA using a small amount of total RNA. Here we have developed a new strategy...
Thu Nov 21, 2019 18:22
British Journal of Cancer, Published online: 22 November 2019; doi:10.1038/s41416-019-0646-8Clinical significance and biological role of L1 cell adhesion molecule in gastric cancer
02:00
The aldehyde dehydrogenases (ALDHs) are a major family of detoxifying enzymes that contribute to cancer progression and therapy resistance. ALDH overexpression is associated with a poor prognosis in many cancer types. The use of multi-ALDH isoform or isoform-specific ALDH inhibitors as anti-cancer agents is currently hindered by the lack of viable candidates. Most multi-ALDH isoform inhibitors lack bioavailability, are non-specific or toxic while most isoform-specific inhibitors are not effective...
Thu Nov 21, 2019 16:59
Purpose:Molecular subtyping for pancreatic cancer has made substantial progress in recent years, facilitating the optimization of existing therapeutic approaches to improve clinical outcomes in pancreatic cancer. With advances in treatment combinations and choices, it is becoming increasingly important to determine ways to place patients on the best therapies upfront. Although various molecular subtyping systems for pancreatic cancer have been proposed, consensus regarding proposed subtypes, as well...
Thu Nov 21, 2019 16:59
Purpose: The majority of deaths from breast cancer occur following the development of metastatic disease, a process inhibited by β-blockers in pre-clinical studies. This phase II randomized controlled trial evaluated the effect of pre-operative β-blockade with propranolol on biomarkers of metastatic potential and the immune cell profile within the primary tumor of patients with breast cancer. Experimental design: In this triple-blind placebo-controlled clinical trial, 60 patients were randomly assigned...
Thu Nov 21, 2019 16:02
Purpose: Neoadjuvant PD-1 blockade is a promising treatment for resectable non-small cell lung cancer (NSCLC), yet immunological mechanisms contributing to tumor regression and biomarkers of response are unknown. Using paired tumor/blood samples from a phase 2 clinical trial (NCT02259621), we explored whether the peripheral T cell clonotypic dynamics can serve as a biomarker for response to neoadjuvant PD-1 blockade. Experimental Design: T cell receptor (TCR) sequencing was performed on serial...
Thu Nov 21, 2019 16:02
Purpose:Statins are associated with lower risk of aggressive prostate cancer, but lethal prostate cancer is understudied and contributing mechanisms unclear. We prospectively examined statins and lethal prostate cancer risk in the Health Professionals Follow-up Study (HPFS), tested associations with molecular subtypes, and integrated gene expression profiling to identify putative mechanisms. Experimental Design:Our study included 44,126 men cancer-free in 1990, followed for prostate cancer incidence...
Thu Nov 21, 2019 10:05
Thu Nov 21, 2019 02:00
Cancers, Vol. 11, Pages 1840: ANLN and TLE2 in Muscle Invasive Bladder Cancer: A Functional and Clinical Evaluation Based on In Silico and In Vitro Data Cancers doi: 10.3390/cancers11121840 Authors: Wu Nitschke Heinkele Weis Worst Eckstein Porubsky Erben : Anilin actin binding protein (ANLN) and transducing-like enhancer protein 2 (TLE2) are associated with cancer patient survival and progression. The impact of their gene expression on progression-free survival...
Thu Nov 21, 2019 02:00
Cancers, Vol. 11, Pages 1841: Reversal of Epithelial–Mesenchymal Transition by Natural Anti-Inflammatory and Pro-Resolving Lipids Cancers doi: 10.3390/cancers11121841 Authors: Lee Epithelial mesenchymal transition (EMT) is a key process in the progression of malignant cancer. Therefore, blocking the EMT can be a critical fast track for the development of anticancer drugs. In this paper, we update recent research output of EMT and we explore suppression of EMT by natural anti-inflammatory...
Thu Nov 21, 2019 02:00
Publication date: Available online 20 November 2019Source: Seminars in OncologyAuthor(s): Saro H. Armenian, Wojciech Jurczak, Joseph R. Carver, Alessandra Gennari, Giorgio Minotti, Michael S. EwerAbstractGuidelines for the diagnosis, management, and surveillance of cancer patients have evolved with the single goal of improving patient care based on available data when available, or in the absence of firm data, on the standard practices of those with broad experience in actual hands-on patient care....
Thu Nov 21, 2019 18:57
Publication date: Available online 21 November 2019Source: Practical Radiation OncologyAuthor(s): John L. Gore, Marguerite du Plessis, Jingbin Zhang, Darlene Dai, Darby J.S. Thompson, Lawrence Karsh, Brian Lane, Michael Franks, David Y.T. Chen, Fernando J. Bianco, Gordon Brown, William Clark, Adam S. Kibel, Hyung Kim, William Lowrance, Murugesan Manoharan, Paul Maroni, Scott Perrapato, Paul Sieber, Edouard J. TrabulsiAbstractPurposeThe optimal management of men with prostate cancer at high risk of...
Thu Nov 21, 2019 17:45
Publication date: Available online 21 November 2019Source: Practical Radiation OncologyAuthor(s): Andrew Oar, Mark Lee, Hien Le, George Hruby, Raymond Dalfsen, David Pryor, Dominique Lee, Julie Chu, Lois Holloway, Adam Briggs, Andrew Barbour, Sarat Chander, Sweet Ping Ng, Jas Samra, John Shakeshaft, David Goldstein, Nam Nguyen, Karyn A. Goodman, Daniel T. Chang, Andrew KneeboneAbstractPurposeNonrandomized data exploring pancreas stereotactic body radiation therapy (SBRT) has demonstrated excellent...
Thu Nov 21, 2019 17:45
Publication date: Available online 21 November 2019Source: Practical Radiation OncologyAuthor(s): Vincent Bernard, Joseph M. Herman
Thu Nov 21, 2019 17:45
Opportunities and challenges of genomically guided decision making for patients with prostate cancer
Publication date: Available online 21 November 2019Source: Practical Radiation OncologyAuthor(s): William A. Hall
Thu Nov 21, 2019 17:45
Cancers, Vol. 11, Pages 1838: Risk of Optic Pathway Glioma in Neurofibromatosis Type 1: No Evidence of Genotype–Phenotype Correlations in A Large Independent Cohort Cancers doi: 10.3390/cancers11121838 Authors: Melloni Eoli Cesaretti Bianchessi Ibba Esposito Scuvera Morcaldi Micheli Piozzi Avignone Chiapparini Pantaleoni Natacci Finocchiaro Saletti The occurrence of optic pathway gliomas (OPGs) in children with neurofibromatosis...
Thu Nov 21, 2019 02:00
Cancers, Vol. 11, Pages 1839: Targeting Calcium Signalling in Malignant Mesothelioma Cancers doi: 10.3390/cancers11121839 Authors: Martinotti Patrone Moccia Ranzato Calcium ions (Ca2+) are central in cancer development and growth, serving as a major signaling system determining the cell's fate. Therefore, the investigation of the functional roles of ion channels in cancer development may identify novel approaches for determining tumor prognosis. Malignant mesothelioma is...
Thu Nov 21, 2019 02:00
Cancers, Vol. 11, Pages 1837: Changes of O6-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse—A Meta-Analysis Type Literature Review Cancers doi: 10.3390/cancers11121837 Authors: Feldheim Kessler Monoranu Ernestus Löhr Hagemann Methylation of the O6-methylguanine DNA methyltransferase (MGMT) promoter has emerged as strong prognostic factor in the therapy of glioblastoma multiforme. It is associated with an improved response to...
Thu Nov 21, 2019 02:00
Thu Nov 21, 2019 11:41
Thu Nov 21, 2019 11:21
Abstract Introduction The orphan nuclear receptor 4A2 (NR4A2) has been extensively characterized in subcellular regions of the brain and is necessary for the function of dopaminergic neurons. The NR4A2 ligand, 1,1-bis (31-indoly1)-1-(p-chlorophenyl)methane (DIM-C-pPhCl) inhibits markers of neuroinflammation and degeneration in mouse models and in this study we investigated expression and function of NR4A2 in glioblastoma (GBM). ...
Thu Nov 21, 2019 02:00
Related ArticlesIncidence and survival trends for appendiceal mucinous adenocarcinoma: an analysis of 3237 patients in the Surveillance, Epidemiology, and End Results database. Future Oncol. 2019 Nov 20;: Authors: Yan Q, Zheng W, Luo H, Wang B, Zhang X, Wang X Abstract Aim: To characterize the epidemiology of appendiceal mucinous adenocarcinoma. Methods: Prognostic factors were evaluated with univariate and multivariate analyses. The results were used...
Thu Nov 21, 2019 15:06
Related ArticlesRadiation-induced intestinal damage: latest molecular and clinical developments. Future Oncol. 2019 Nov 20;: Authors: Lu L, Li W, Chen L, Su Q, Wang Y, Guo Z, Lu Y, Liu B, Qin S Abstract Aim: To systematically review the prophylactic and therapeutic interventions for reducing the incidence or severity of intestinal symptoms among cancer patients receiving radiotherapy. Materials & methods: A literature search was conducted in the...
Thu Nov 21, 2019 15:06
Related ArticlesThe effect of marital status on endometrial cancer-related diagnosis and prognosis: a Surveillance Epidemiology and End Results database analysis. Future Oncol. 2019 Nov 20;: Authors: Dong J, Dai Q, Zhang F Abstract Aim: Marital status has been proved a significant prognostic factor for diagnosis and prognosis in various cancers, but the effect in endometrial cancer (EMC) is controversial. The research was designed to clarify the relationship...
Thu Nov 21, 2019 15:06
Related ArticlesRegorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND). Future Oncol. 2019 Nov 20;: Authors: Bozzarelli S, Rimassa L, Giordano L, Sala S, Tronconi MC, Pressiani T, Smiroldo V, Prete MG, Spaggiari P, Personeni N, Santoro A Abstract Aim: Regorafenib may be active in different cancer types. This Phase II trial included patients with various refractory cancer types treated with regorafenib. Here,...
Thu Nov 21, 2019 15:06
Related ArticlesBevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer. Future Oncol. 2019 Nov 20;: Authors: Haunschild CE, Tewari KS Abstract On 13 June 2018, Genentech, Inc. issued a press release announcing that the US FDA had approved the antiangiogenesis drug, bevacizumab, in combination with chemotherapy for frontline and maintenance therapy for women with newly diagnosed ovarian cancer. Regulatory approval was...
Thu Nov 21, 2019 15:06
Cancers, Vol. 11, Pages 1832: Targeting STAT3 and STAT5 in Tumor-Associated Immune Cells to Improve Immunotherapy Cancers doi: 10.3390/cancers11121832 Authors: Verdeil Lawrence Schmitt-Verhulst Auphan-Anezin Oncogene-induced STAT3-activation is central to tumor progression by promoting cancer cell expression of pro-angiogenic and immunosuppressive factors. STAT3 is also activated in infiltrating immune cells including tumor-associated macrophages (TAM) amplifying immune...
Thu Nov 21, 2019 02:00
Cancers, Vol. 11, Pages 1835: Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial Cancers doi: 10.3390/cancers11121835 Authors: Dubois Keller Hoflack Maille Antoine Westeel Bergot Quoix Lavolé Bigay-Game Pujol Langlais Morin Zalcman Levallet RASSF1 gene methylation predicts...
Thu Nov 21, 2019 02:00
Cancers, Vol. 11, Pages 1833: JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL Cancers doi: 10.3390/cancers11121833 Authors: Wahnschaffe Braun Timonen Giri Schrader Wagle Almusa Johansson Bellanger López Haferlach Stern Dürig Siebert Mustjoki Aittokallio Herling T-cell prolymphocytic leukemia (T-PLL) is a rare and poor-prognostic mature T-cell leukemia. Recent studies detected genomic aberrations affecting...
Thu Nov 21, 2019 02:00
Cancers, Vol. 11, Pages 1834: Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia Cancers doi: 10.3390/cancers11121834 Authors: Puła Gołos Górniak Jamroziak Ibrutinib is the first Bruton’s tyrosine kinase (BTK) inhibitor, which showed significant clinical activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patients regardless of cytogenetic risk factors. Recent results of phase III clinical trials in treatment-naïve...
Thu Nov 21, 2019 02:00
Cancers, Vol. 11, Pages 1836: Cancer Cell Membrane-Coated Nanoparticles for Cancer Management Cancers doi: 10.3390/cancers11121836 Authors: Harris Scully Day Cancer is a global health problem in need of transformative treatment solutions for improved patient outcomes. Many conventional treatments prove ineffective and produce undesirable side effects because they are incapable of targeting only cancer cells within tumors and metastases post administration. There is a desperate...
Thu Nov 21, 2019 02:00
Abstract This study aimed to assess the clinical value of C-reactive protein-albumin ratio (CAR) at the initiation of first-line treatment for castration-resistant prostate cancer (CRPC). We identified 221 CRPC patients treated with either androgen-signaling inhibitors (ASIs: abiraterone and enzalutamide) or docetaxel as the first-line treatment. The value of CAR was evaluated at the initiation of first-line treatment. The optimal cutoff value of CAR for the prediction of lethality...
Thu Nov 21, 2019 02:00
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου